Last update 21 Nov 2024

Dextromethorphan Hydrobromide Hydrate

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryDextromethorphan (DXM) is a synthetic analog of codeine, but unlike codeine, it is not a narcotic and does not have the same potential for abuse or addiction. DXM is an N-methyl-D-aspartate (NMDA) receptor antagonist, NMDA receptors are involved in pain perception and the regulation of mood, learning, and memory. DXM is a sigma-1 receptor agonist,Sigma-1 receptors are involved in many different functions, including pain perception, mood regulation, and neuroprotection. Dextromethorphan is commonly used as a cough suppressant, and it has also been investigated for its potential therapeutic effects in a variety of conditions, including neuropathic pain, depression, and addiction. Dextromethorphan was successfully tested in 1954 as part of US Navy and CIA-funded research on nonaddictive substitutes for codeine. It was approved by the FDA in 1958 as an over-the-counter antitussive.

Drug Type

Small molecule drug

Synonyms

Dextromethorphan Hydrobromide, Dextromethorphan Hydrobromide Cranules, Dextromethorphan Hydrobromide Granules

+ [29]

Target

NMDA receptor x σ1 receptor

Mechanism

NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists), σ1 receptor agonists(Sigma opioid receptor agonists)

Therapeutic Areas

Respiratory Diseases

Active Indication

Dry coughCough

Inactive Indication-

Originator Organization

Shionogi Pharma Co., Ltd.

Active Organization

Shionogi Pharma Co., Ltd.

Guangzhou Baiyunshan Guang Hua Pharmacy Co., Ltd.Tsuruhara Pharmaceutical Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (01 Jan 1958),

Cough

Regulation-

Structure

Molecular FormulaC18H28BrNO2

InChIKeySTTADZBLEUMJRG-IKNOHUQMSA-N

CAS Registry6700-34-1

155

Clinical Trials associated with Dextromethorphan Hydrobromide Hydrate

NCT06383338 / Not yet recruitingPhase 1

A Prospective Feasibility Study Investigating PhEnoconversion of CYP3A4, CYP2C19 and CYP2D6 Genotype in Paediatric and Adolescent and Young Adult patientS With an acUte diagnosiS of Hodgkin or Non-Hodgkin Lymphoma.

PEGASUS aims to test acceptability and feasibility of studying phenoconversion (the change in metabolism phenotype) using probe medications in a paediatric oncology patient population. The study will be conducted in patients (6-25 years of age) with Hodgkin lymphoma or non-Hodgkin lymphoma as exemplar cohort, but with the understanding that cancer-directed and supportive care medicines of the CYP3A4, CYP2C19, and CYP2D6 metabolic pathways are commonly utilised for the treatment of many paediatric, adolescent, young adult, and adult cancers.
The study involves administration of the probe medication at timepoints which align with pre-determined hospital visits for the treatment of lymphoma and subsequent blood draws to measure the metabolism of the probe medications.
The acceptability and feasibility of this study will inform future studies in phenoconversion within the paediatric cancer population to direct more personalised precision medicine.

Start Date01 Mar 2025

Sponsor / Collaborator

Murdoch Childrens Research Institute

NCT06632990 / Not yet recruitingPhase 1

An Open-label, Randomized, Three-arm Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates in Healthy Adult Participants

The goal of this study is to learn if the investigational drug, BMS-984923 will impact the exposure and clearance of other medications when given together. Most drugs are broken down and cleared in the body via cytochrome P450 enzymes in the liver. The metabolism and clearance of certain drugs can be affected by other drugs when dosed together. To evaluate the impact of BMS-984923 on the clearance of other medications, we will investigate three known pathways which may be impacted by BMS-984923.
In this study participants will take one dose of the three known medications, midazolam, caffeine and dextromethorphan together. These drugs are known to be cleared by different cytochrome P450 enzymes. Blood will be collected to evaluate the exposure and clearance of these medications and their primary metabolites. Study participants will then be administered BMS-984923 for 18-days. On the 18th Day of BMS-984923 dosing, participants will again be co-administering midazolam, caffeine and dextromethorphan. Blood will be collected again, and the concentration of each drug will be measured. We will learn in this study if BMS-984923 changes the exposure and metabolism of the known drugs. These results will inform how BMS-984923 can be administered to patients who take multiple medications.

Start Date01 Nov 2024

Sponsor / Collaborator

Allyx Therapeutics, Inc.Startup

[+1]

ChiCTR2400090574 / SuspendedEarly Phase 1IIT

The Effectiveness and Safety of Dextromethorphan Hydrobromide Nasal Spray for Pre-Magnetic Resonance Imaging Sedation in Children

Start Date14 Oct 2024

Sponsor / Collaborator

The Children's Hospital of Zhejiang University School of Medicine

100 Clinical Results associated with Dextromethorphan Hydrobromide Hydrate

100 Translational Medicine associated with Dextromethorphan Hydrobromide Hydrate

100 Patents (Medical) associated with Dextromethorphan Hydrobromide Hydrate

2,706

Literatures (Medical) associated with Dextromethorphan Hydrobromide Hydrate

31 Dec 2024·Journal of Medical Economics

Real-world treatment patterns of patients with major depressive disorder treated with Auvelity in the United States

Article

Author: Zhao, Yang ; Syed, Fatima Zahara ; Cong, Junjun ; Zhou, Huanxue ; Tabuteau, Herriot ; Muzyk, Andrew

AIMSMajor depressive disorder (MDD) is a prevalent, chronic disorder. Auvelity (dextromethorphan-bupropion) is a novel, oral N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist approved (August 2022) by the FDA for treating MDD in adults. This is the first analysis on real-world Auvelity usage in the United States.METHODSAdult patients initiating Auvelity in the Symphony IDV databases by September 2023 were identified (index date: the first Auvelity claim). Patients had continuous eligibility over the 12-month pre-index period and ≥1 MDD diagnosis (ICD-10-CM codes: F32.*, F33.*) over the 5-year pre-index period. Demographic and clinical characteristics, comorbidities, prior MDD-related medications, and Auvelity initiation status were assessed.RESULTSThis analysis included 22,288 patients with MDD treated with Auvelity (mean age 45.1 years; 68.1% women); 40.0% lived in the South and 58.5% had commercial insurance. Comorbidities included mental health disorders (53.5%; 47.6% had anxiety disorders). Overall, 83.7% of the patients had received treatment with selective serotonin reuptake inhibitors (SSRIs; 54.9%), the norepinephrine-dopamine reuptake inhibitor (NDRI [bupropion]; 40.4%), and/or serotonin-norepinephrine reuptake inhibitors (SNRIs; 35.9%) over the 12-month pre-index period. The last MDD-related treatment prior to Auvelity comprised SSRI (22.4%), SNRI (13.2%), and NDRI (12.8%) monotherapies; 294 (1.3%) patients received esketamine. In total, 6,418 (28.8%) patients initiated Auvelity as monotherapy vs 15,870 (71.2%) as an add-on; Auvelity was most frequently added to an SSRI alone (10.7%) or SNRI alone (6.5%). A total of 2,254 (10.1%) patients initiated Auvelity without prior treatment in the 12-month pre-index period.LIMITATIONSIncomplete data due to reporting; diagnoses captured subject to coding error; and limited generalizability to other populations.CONCLUSIONSUsing a large demographically distributed claims database, 22,288 patients with MDD initiated Auvelity within a year of its approval; 10.1% were treatment-naïve and 28.8% initiated Auvelity as monotherapy. Most patients had mental health-related comorbidities and attempted various MDD-related treatments prior to Auvelity.

01 Dec 2024·Psychiatry and Clinical Neurosciences Reports

Concomitant use of dextromethorphan and alcohol‐induced dissociation in a patient with alcohol dependence

Article

Author: Tajima, Yuko ; Nagai, Yasuhito ; Miyakawa, Koichi

AbstractBackgroundDextromethorphan (DXM) is an over‐the‐counter drug that is commonly abused by teenagers. Its main pharmacological property is a low‐affinity N‐methyl‐d‐aspartate (NMDA) receptor antagonist.Case PresentationWe report acute psychotic dissociation induced by DXM and alcohol in a patient with alcohol dependence, which made it difficult to distinguish alcohol withdrawal symptoms with limited information. The psychotic symptoms were ameliorated by haloperidol; however, in cases of DXM abuse, haloperidol treatment should be avoided.ConclusionIn the consultation of patients with addiction, the possibility of various addictive drugs must be kept in mind. The concomitant use of DXM and alcohol causes easy dissociation and high‐dose usage of DXM and alcohol withdrawal symptoms are difficult to distinguish.

01 Nov 2024·Drug Metabolism and Disposition

Assessing Trends in Cytokine–CYP Drug Interactions and Relevance to Drug Dosing

Article

Author: Dai, David ; Phipps, Alex ; Vishwanathan, Karthick ; Sawant-Basak, Aarti ; Olabode, Damilola

The regulation of drug-metabolizing enzymes and transporters by cytokines has been extensively studied, in vitro and in clinic. Cytokine-mediated suppression of CYPs or drug transporters may increase or decrease the systemic clearance of drug substrates that are primarily cleared via these pathways; neutralization of cytokines by therapeutic proteins may thereby alter systemic exposures of such drug substrates. The FDA recommends evaluating such clinical drug interactions during clinical development and has provided labeling recommendations for therapeutic proteins. To determine the clinical relevance of these drug interactions to dose adjustments, trends in steady-state exposures (AUC_ss) of CYP-sensitive substrates co-administered with cytokine modulators as reported in the UW DIDB were extracted and examined for each of the CYPs. Co-administration of CYP3A (midazolam/simvastatin), CYP2C19 (omeprazole), or CYP1A2 (caffeine/tizanidine) substrates with anti-IL-6 and with anti-IL-23 therapeutics led to changes in systemic exposures of CYP substrates ranging from ~ -58% to ~35%; no significant trends were observed for CYP2D6 (dextromethorphan) and CYP2C9 (warfarin) substrates. Although none of these changes in systemic exposures have been reported as clinically meaningful, dose adjustment of midazolam for optimal sedation in acute care settings has been reported. Simulated concentration-time profiles of midazolam under conditions of elevated cytokine levels when co-administered with tocilizumab, suggest a ~6-7 fold increase in midazolam clearance suggesting potential implications of cytokine- CYP drug interactions on dose adjustments of sensitive CYP3A substrates in acute care settings. Additionally, this article also provides a brief overview of non-clinical and clinical assessments of cytokine-CYP drug interactions, in drug discovery and development. Significance Statement Significance statement: There has been significant progress in understanding cytokine-mediated drug interactions for CYP-sensitive substrates. This article provides an overview of the progress in this field, including a trend analysis of systemic exposures of CYP-sensitive substrates co-administered with anti-IL-x therapeutics. In addition, the review also provides a perspective of current methods used to assess these drug interactions during drug development, and a focus on individualized medicine, particularly in acute care settings.

News (Medical) associated with Dextromethorphan Hydrobromide Hydrate

07 Nov 2024

·www.prnewswire.com

FDA Proposes Ending Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient After Extensive Review

SILVER SPRING, Md., Nov. 7, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration announced it is proposing to remove oral phenylephrine as an active ingredient that can be used in over-the-counter (OTC) monograph drug products for the temporary relief of nasal congestion after an agency review of the available data determined that oral phenylephrine is not effective for this use. For now, companies may continue to market OTC monograph drug products containing oral phenylephrine as a nasal decongestant. This is a proposed order. Only a final order will affect what products can be marketed. The proposed order is based on effectiveness concerns, not on safety concerns. Currently, oral phenylephrine is widely used as a nasal decongestant active ingredient in many OTC monograph drug products. It is important to note that some products only contain oral phenylephrine as a single, active ingredient. Others contain oral phenylephrine and another active ingredient (e.g., acetaminophen or dextromethorphan), and the presence of oral phenylephrine in these medicines does not affect how other active ingredients work to treat the symptoms for which they are intended. "It is the FDA's role to ensure that drugs are safe and effective," said Patrizia Cavazzoni, M.D., director of the FDA's Center for Drug Evaluation and Research (CDER). "Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this next step in the process to propose removing oral phenylephrine because it is not effective as a nasal decongestant." The agency conducted a comprehensive review of all available data on the safety and efficacy of oral phenylephrine, including the historical data that were used to support the determination made 30 years ago that oral phenylephrine was effective as a nasal decongestant, as well as newer clinical data on oral phenylephrine that have since become available. Last fall, the FDA also held a Nonprescription Drug Advisory Committee meeting to discuss the 'Generally Recognized as Safe and Effective' (GRASE) status of oral phenylephrine as a nasal decongestant. The committee discussed new data on the effectiveness of orally administered phenylephrine and unanimously concluded that the current scientific data do not support that the recommended dosage in the OTC cold, cough, allergy, bronchodilator and antiasthmatic drug products monograph for orally administered phenylephrine's effectiveness as a nasal decongestant. "Consumers should know that a range of safe and effective drugs and other treatments is available to temporarily relieve congestion symptoms due to allergies or a common cold," said Theresa Michele, M.D., director of the Office of Nonprescription Drug Products in CDER. "Consumers can also talk to their doctor or pharmacist about ways to treat these symptoms." Because a variety of different drug products may be sold under the same brand name, consumers should always read the Drug Facts label to determine which ingredients are in a medication, and to be aware of important warnings and directions for use. Phenylephrine is also an ingredient in nasal sprays to treat congestion. The FDA's action is only related to orally administered phenylephrine and not the nasal spray form. The FDA is seeking public comments on this proposed order. Instructions on how to submit comments are found in the proposed order available on OTC Monographs@FDA. If, after considering the comments, the FDA concludes oral phenylephrine is not effective as a nasal decongestant, the FDA will issue a final order removing oral phenylephrine from the OTC monograph, and drug products thereafter could no longer contain oral phenylephrine as a nasal decongestant. The FDA would provide manufacturers with appropriate time to either reformulate drugs containing oral phenylephrine or remove such drugs from the market. Additional Information: Key Information about Nonprescription, Over-the-Counter (OTC), Oral Phenylephrine Federal Register: Public Inspection: Over-the-Counter Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use FDA clarifies results of recent advisory committee meeting on oral phenylephrine September 11-12, 2023: Meeting of the Nonprescription Drugs Advisory Committee OTC Drug Review Process Annual Forecast for Planned Monograph Activities Monograph M012: Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use OTC Monographs Frequently Asked Questions Media Contact: Cherie Duvall-Jones, (301) 357-0607 Consumer Inquiries: Email, 888-INFO-FDA The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and for regulating tobacco products. SOURCE U.S. Food and Drug Administration WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

07 Nov 2024

·endpts.com

FDA seeks to pull OTC nasal decongestant ingredient due to lack of efficacy

After 17 years of back and forth with citizen petitions and two advisory committees, the FDA on Thursday proposed to pull commonly-used nasal decongestant active ingredients in common over-the-counter drugs like Sudafed found to be ineffective. The 56-page proposed order and scientific review explain how oral phenylephrine is widely used as a nasal decongestant active ingredient in many OTC drugs after an agency review of the available data shows it’s not effective. “Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this next step in the process to propose removing oral phenylephrine because it is not effective as a nasal decongestant,” Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a statement. It’s been a long road to pulling the ingredient for the FDA, and products will only be pulled if this proposed order is finalized. Back in 2007, FDA’s Nonprescription Drugs Advisory Committee recommended that more clinical data were needed to evaluate the safety and effectiveness of oral phenylephrine as an OTC nasal decongestant for patients 12 years and older. In September 2023 , FDA’s adcomm discussed new data on the effectiveness of oral phenylephrine and concluded unanimously that the data do not support that the recommended dosage of orally administered phenylephrine is effective as a nasal decongestant, the agency said. Neither the FDA nor the adcomm raised safety concerns with use of oral phenylephrine at the recommended dose. “It is important to note that some products only contain oral phenylephrine as a single, active ingredient,” the agency said in a statement. “Others contain oral phenylephrine and another active ingredient (e.g., acetaminophen or dextromethorphan), and the presence of oral phenylephrine in these medicines does not affect how other active ingredients work to treat the symptoms for which they are intended.” The FDA’s proposal is also only related to orally administered phenylephrine and not the nasal spray form. “Consumers should know that a range of safe and effective drugs and other treatments is available to temporarily relieve congestion symptoms due to allergies or a common cold,” said Theresa Michele, the director of the Office of Nonprescription Drugs in CDER. “Consumers can also talk to their doctor or pharmacist about ways to treat these symptoms.” The Consumer Healthcare Products Association’s President and CEO Scott Melville came out against the move by FDA, saying in a statement , “CHPA is disappointed in FDA’s proposal to reverse its long-established view of oral PE. For decades, people have relied on oral PE to relieve their nasal congestion. We believe Americans deserve access to safe and effective OTC medicines and the option to choose the products they prefer for self-care.”

07 Nov 2024

·www.drugs.com

FDA Proposes Ban on a 'Useless' Decongestant, Phenylephrine

THURSDAY, Nov. 7, 2024 -- More than a year after its advisory panel unanimously declared the drug phenylephrine to be useless against nasal congestion , the U.S. Food and Drug Administration is proposing that it be removed from common over-the-counter decongestants. Products that include phenylephrine as an active ingredient include Sudafed PE, Vicks Sinex and Benadryl Allergy Plus Congestion. In fact, "it is important to note that some products only contain oral phenylephrine as a single, active ingredient," the FDA said in a statement released Thursday. However, based on the available science, it's time for consumers to stop throwing their money away on such products, the FDA said. "It is the FDA's role to ensure that drugs are safe and effective," Dr. Patrizia Cavazzoni , who directs the FDA's Center for Drug Evaluation and Research (CDER), said in the statement. "Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this next step in the process to propose removing oral phenylephrine because it is not effective as a nasal decongestant.” The agency said its experts pored over decades of data on whether or not phenylephrine could ease nasal congestion. They found no evidence to support the claim, nor any evidence to support the notion that phenylephrine might boost the effects of other medicines included in a decongestant, such as acetaminophen or dextromethorphan. At this point, the FDA's move remains a proposal only; the agency will accept comments on it until May 7, after which time the agency may move to a final order to remove phenylephrine from store shelves. Right now, the FDA's proposal is only related to phenylephrine taken as a pill or syrup, not the nasal spray form. Speaking at the time of the FDA advisory panel's vote, Jennifer Schwartzott, the patient representative on the panel, told that Associated Press that “I feel this drug in this oral dose should have been removed from the market a long time ago. Patients require and deserve medications that treat their symptoms safely and effectively, and I don’t believe that this medication does that.” Medications with phenylephrine took on more prominence after the highly effective decongestant pseudoephedrine became harder to purchase in 2005, as part of legislation aimed at combatting the meth epidemic. More than 242 million bottles or packages of phenylephrine-containing cold remedies were sold in 2022, compared with about 51 million cold products containing pseudoephedrine, FDA briefing documents for the meeting show. “We believe that these new clinical pharmacology and clinical data are consistent, substantial and believable, and they confirm that orally administered phenylephrine is not effective at any dose that can be developed and still provide a reasonable margin of safety,” the documents said. This prompted the FDA to review the studies that had been used to approve phenylephrine. “We noted significant methodological and statistical issues with the design and conduct of the original studies submitted to and evaluated by the panel,” the documents stated. The problem appears to be that the body doesn’t absorb phenylephrine well enough to make it useful. Higher doses might work, but those doses would cause blood pressure to spike significantly. “Therefore, in addition to lack of efficacy, there may be no path to evaluating higher doses of oral phenylephrine as a nasal decongestant,” the FDA concluded. An industry group, the Consumer Healthcare Products Association (CHPA), argued against the FDA’s position before the agency’s panel last year. “Considering the data from multiple clinical trials demonstrating effectiveness and decades of in-market experience, CHPA urges the panel to recognize phenylephrine’s clear benefits and critical role in public health,” CHPA Vice President of Regulatory & Scientific Affairs Marcia Howard said in a statement to the committee. The CHPA also asked the panel to consider the potential impact on consumers. “Simply put, the burdens created from decreased choice and availability of these products would be placed directly onto consumers and an already-strained U.S. health care system, which is why CHPA encourages the panel to consider the real-world experience and needs of consumers when making decisions that will have such broad implications,” Howard added. But in its statement issued Thursday, the FDA said consumers do have alternatives to phenylephrine when noses get stuffy. "Consumers should know that a range of safe and effective drugs and other treatments is available to temporarily relieve congestion symptoms due to allergies or a common cold," Dr. Theresa Michele, director of the Office of Nonprescription Drug Products at CDER. "Consumers can also talk to their doctor or pharmacist about ways to treat these symptoms.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

100 Deals associated with Dextromethorphan Hydrobromide Hydrate

External Link

KEGG	Wiki	ATC	Drug Bank
-	Dextromethorphan Hydrobromide Hydrate	R05DA09	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dry cough	CN	Guangzhou Baiyunshan Guang Hua Pharmacy Co., Ltd.	01 Jan 1990
Cough	US	Shionogi Pharma Co., Ltd.	01 Jan 1958

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03864042 (CTgov)	Phase 1	Advanced Malignant Solid Neoplasm \| Metastatic melanoma \| Unresectable Melanoma \| BRAF V600 mutation-positive Melanoma	56	omeprazole+encorafenib+midazolam+caffeine+binimetinib+dextromethorphan+losartan (Arm 1 - CYP Probe Cocktail)	ihnjhzvqpw(nxfwitfrpp) = iwrfzxgiwx zuwypkeeuu (wcytyobhzk, okxuxhpchx - qlcxtcquou) View more	-	27 Sep 2024
				rosuvastatin+bupropion immediate release (IR)+encorafenib+binimetinib (Arm 2 - Rosuvastatin and Bupropion)	rtpjoiknhh(pjvjcjnoeu) = ctkjqsfkha kooozgaaej (bjlvxhtavg, kqpjernfih - jowpxomldl) View more
NCT04392011 (CTgov)	Early Phase 1	-	15	midazolam HCl+dextromethorphan HBr (Drug Cocktail)	qfvrnkltif(jmozgrjico) = ehmxkvscja zvsbqaoyzv (mxjekwfgcl, cxpjfzhqxc - kadjszvwly) View more	-	08 Jun 2023
				Kratom (Kratom + Drug Cocktail)	qfvrnkltif(jmozgrjico) = rreyurtdgx zvsbqaoyzv (mxjekwfgcl, ezxinmfopy - nvqciptkbd) View more
NCT03883581 (CTgov)	Phase 1/2	Amyotrophic Lateral Sclerosis	28	dextromethorphan HBr+quinidine sulfate	wcbsoysmgn(oknzyutzgv) = ezjkfsejvf qbmkosjkff (okdsqqrwog, rturgmoxaj - ieditcnvyx) View more	-	08 Mar 2023
Pubmed	Not Applicable	Cough	112	Dextromethorphan syrup 30 ml (90 mg)	yfpbyyeylq(iclakobrxz) = ogeherdqtm ytkieixaiy (cyivbhxctr ) View more	-	10 Jan 2023
				Placebo	yfpbyyeylq(iclakobrxz) = nbafdfmpyc ytkieixaiy (cyivbhxctr ) View more
NCT03538054 (CTgov)	Phase 2	Fibromyalgia	27	Dextromethorphan (Dextromethorphan)	rqnknsoeag(rgdyswcfjv) = okgwkbncrs wpuntpwdic (wrjxhggrum, bpbcrsejxt - hhuhxyvquo) View more	-	26 Aug 2022
				Placebo (Placebo)	rqnknsoeag(rgdyswcfjv) = ajminadhmf wpuntpwdic (wrjxhggrum, olczqzqqsq - rcnsuylbnv) View more
NCT02651116 (CHPA DXM, CTgov)	Phase 4	Cough	131	Cough recording device+Dextromethorphan Hydrobromide (Dextromethorphan Hydrobromide)	gdjtubttft(vvhcawhgcl) = awuemebyxa tqcwzhmbgx (ocvdbysmgr, zxaznuvabh - dkvqvywiob) View more	-	28 Apr 2021
				Cough recording device (Placebo)	gdjtubttft(vvhcawhgcl) = hbohwzrmsk tqcwzhmbgx (ocvdbysmgr, tavxayuwrc - crukqewagz) View more
NCT03714919 (CTgov)	Phase 2	Hypertrophy of adenoids	10	Dexmedetomidine+Acetaminophen+Dextromethorphan+Ketamine	zqhayvqfea(jypxuwmgva) = heubugvtgz eisvlljrra (nmufzpmzik, lhamumjrii - tdftiycafj) View more	-	05 Feb 2021
NCT03480009 (DexMab, CTgov)	Phase 3	Abortion, Habitual \| Pain	156	Dextromethorphan Hydrobromide+Oxycodone (Dextromethorphan, Opted for Narcotic Prescription)	chxbzqmfsc(hhnufzdayy) = luoqpnrakd iwkmrbkutt (zzpfjjssac, upiqkkslvr - pmqolmipcg) View more	-	06 Aug 2020
				Avicel PH101 (Microcrystalline Cellulose NF) for Compounding+Oxycodone (Placebo, Opted for Narcotic Prescription)	chxbzqmfsc(hhnufzdayy) = lfwhqykyoj iwkmrbkutt (zzpfjjssac, uxpryfxcta - lcbnwhrxmw) View more
NCT03415243 (CTgov)	Phase 1	Common Cold	28	Theraflu+Acetaminophen+Phenylephrine+Dextromethorphan (Treatment Group A)	xlclbuazke(zlaoitpnnl) = qutgkymgap lrqkkhkcgd (tuuephclkv, iikfdwfgxs - dajvmzxybg) View more	-	24 Jun 2019
				Acetaminophen+Phenylephrine+Dextromethorphan (Treatment Group B)	xlclbuazke(zlaoitpnnl) = qpdezncmui lrqkkhkcgd (tuuephclkv, wyrcyptcqf - vgzyoftxyy) View more
NCT02775240 (CTgov)	Phase 1	Cytomegalovirus Infections	18	digoxin+dextromethorphan (Treatment A)	nxvqzvzwhe(uddonpirdc) = mosfjbuooh fviddqmnxh (wibddducah, ojukthjako - xlfrosdhke) View more	-	16 Jan 2019
				digoxin+maribavir+dextromethorphan (Treatment B)	nxvqzvzwhe(uddonpirdc) = pcobmmmzjk fviddqmnxh (wibddducah, ojikizmtwa - dpxiytylkv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis